Appropriate Use Criteria (AUC) are statements that contain indications describing when, and how often, an intervention should be performed under the auspices of scientific evidence, clinical judgment, and patient values while avoiding unnecessary provisions of services. SNMMI follows a balanced multidisciplinary approach to guidance development by including various stakeholders in the development process. To view the development process, please click the following link: SNMMI AUC Development Process.
Click here to get answers to your reimbursement questions regarding Appropriate Use Criteria.
Comments or Questions?
The SNMMI Guidance Oversight Committee is continually developing new Appropriate Use Criteria (AUC) and reviewing and updating existing AUC. If you have specific comments or questions on the content of any of the AUC, or if you have suggestions for new AUC that you feel should be written, please contact the SNMMI Guidance Oversight Committee at auc@snmmi.org. All comments will be considered in the AUC development process.
Approved
|
Date Approved
|
Last Update
|
Document Title
|
| April 26, 2023 |
|
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
|
| January 8, 2023 |
|
Appropriate Use Criteria for the Use of Nuclear Medicine in Fever of Unknown Origin
• Click here for a printer friendly Fact Sheet version
|
| October 8, 2022 |
|
Estrogen Receptor-Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol
• Click here for a printer friendly Fact Sheet version
• Video: Drs. Gary Ulaner & Jason Mouabbi discuss the AUC for FES PET
|
| October 8, 2022 |
|
Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema
• Click here for a printer friendly Fact Sheet version
|
| September 15, 2021 |
March 24,2022
|
Prostate-Specific Membrane Antigen (PSMA) PET Imaging
• Click here for a printer friendly Fact Sheet version
• Video: Dr. Hossein Jadvar discusses the AUC for PSMA PET imaging
|
| March 15, 2021 |
|
Musculoskeletal Infection Imaging (submitted to JNM in March) |
| March 29, 2020 |
|
PET Myocardial Perfusion Imaging (MPI) |
| September 27, 2019 |
|
Imaging Evaluation of Biochemical Recurrence of Prostate Cancer Following Definitive Primary Treatment
• Click here for a printer friendly Fact Sheet version
|
| September 27, 2019 |
|
Nuclear Medicine in Evaluation and Treatment of Differentiated Thyroid Cancer
|
| September 27, 2019 |
|
Gastrointestinal Transit
• Click here for a printer friendly Fact Sheet version
|
| September 9, 2017 |
October 2020 |
Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
• Click here for a printer friendly Fact Sheet version
|
| June 9, 2017 |
August 2020 |
FDG PET/CT Restaging and Response Assessment of Malignant Disease
|
| June 5, 2017 |
August 2020 |
Hepatobiliary Scintigraphy in Abdominal Pain
|
| January 20, 2017 |
August 2020 |
Ventilation/Perfusion (V/Q) Imaging in Pulmonary Embolism
• Click here for a printer friendly Fact Sheet version
• Video: Drs. Alan Waxman, Sam Torbati, and Victor Tapson discuss the AUC for Ventilation/Perfusion imaging
|
| January 20, 2017 |
August 2020 |
Bone Scintigraphy in Prostate and Breast Cancer
• Click here for a printer friendly Fact Sheet version
|
| January 28, 2013 |
|
Amyloid Imaging
|
Currently Under Development
|
|
Brain Imaging (including Amyloid and Tau)
|
|
Molecular Breast Imaging
|
|
PET for Initial Staging of Neoplastic Disease
|
| |
To Be Developed
|
|
Brain Imaging with HMPO and DAT
|
|
Benign Tumors of Thyroid
|
|
Radium 223
|
|
Renal Imaging
|
Feedback
|
|
Please let us know if you have any suggestions for future topics for AUC development, or any feedback on the existing publications by contacting us at quality@snmmi.org.
|
Available for Public Comment
|
| As part of the development process, the SNMMI Guidance Oversight Committee will seek public comment on draft documents in order to ensure we are creating the most accurate guidelines. To submit comments on an AUC, please complete the response form and submit to auc@snmmi.org. Below are AUC for which we are currently seeking public input: |
Comments Due By
|
|
Document Title
|
|
April 17, 2023
|
|
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy |
